Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Nov;45(11):3242-5.
doi: 10.1128/AAC.45.11.3242-3245.2001.

Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes

K Nagai  1 , T A Davies, L M Ednie, A Bryskier, E Palavecino, M R Jacobs, P C Appelbaum
Affiliations
Comparative Study

Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes

K Nagai et al. Antimicrob Agents Chemother. 2001 Nov.

Abstract

Activities of HMR 3787 and RU 64399 were compared to those of three macrolides, telithromycin, and clindamycin against 175 Streptococcus pneumoniae isolates and 121 Streptococcus pyogenes isolates. HMR3787 and telithromycin were the most active compounds tested against pneumococci. Telithromycin and RU 64399 were equally active against macrolide-susceptible (MICs, 0.008 to 0.06 microg/ml) and -resistant S. pyogenes isolates, but HMR 3787 had lower MICs for ermB strains.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Chemical structures of HMR 3787 and RU 64339.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Alos J I, Aracil B, Oteo J, Torres C J L, Gomez-Garcés the Spanish Group for the Study of Infection in the Primary Health Care Setting. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M-phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. J Antimicrob Chemother. 2000;45:605–609. - PubMed
    1. Arpin C, Canton M-H, Noury P, Quentin C. Emergence of mefA and mefE genes in beta-hemolytic streptococci and pneumococci in France. J Antimicrob Chemother. 1999;44:133–134. - PubMed
    1. Arthur M, Molinas C, Mabilat C, Courvalin P. Detection of erythromycin resistance by the polymerase chain reaction in conserved regions of erm rRNA methylase genes. Antimicrob Agents Chemother. 1990;34:2024–2026. - PMC - PubMed
    1. Barry A L, Fuchs P C, Brown S D. Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA J. Antimicrob Chemother. 1997;40:139–140. - PubMed
    1. Bemer-Melchior P, Juvin M-E, Tassin S, Bryskier A, Schito G C, Drugeon H-B. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother. 2000;44:2999–3002. - PMC - PubMed

Publication types

MeSH terms